Search - tctmd.com

Displaying 1 - 16 of 16

Sort: Relevancy | Date

News Daily News

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

Michael O'Riordan

December 12, 2025

News Daily News

Better Outcomes and Lower Cost with Bariatric Surgery Over GLP-1s

Michael O'Riordan

September 18, 2025

News Daily News

Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT

Michael O'Riordan

July 31, 2025

SELECT: Semaglutide’s Impact on CVD Events Emerges Quickly

Michael O'Riordan

May 14, 2025

News Conference News AHA 2024

US Obesity Epidemic Continues to Skyrocket, With No End in Sight

Michael O'Riordan

November 15, 2024

News Daily News

Bariatric Surgery Reduces Hard Events in Obese Patients With Sleep Apnea

Michael O'Riordan

June 21, 2024

News Opinion CV Team Dispatch

April 2024 Dispatch for the CV Team

L.A. McKeown

April 01, 2024

News Daily News

One in Three Overweight MI Patients May Benefit From Semaglutide

Todd Neale

February 26, 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for December 2023

Caitlin E. Cox

December 28, 2023

News Daily News

Top Coronary Artery Disease News of 2023

Michael O'Riordan

December 22, 2023

News Daily News

Diabetes in Middle Age Linked to Earlier CVD Risk: Danish Study

L.A. McKeown

October 10, 2023

News Features

Skyrocketing Popularity Puts GLP-1 Agonists for Weight Loss on Cardiology’s Radar

L.A. McKeown

May 12, 2023

News Daily News

Fewer MACE in Diabetic Patients Taking SGLT2 Inhibitors vs DPP-4 Inhibitors

Shelley Wood

September 30, 2020

News Daily News

New Guidance on Use of Diabetes Drugs for CVD Risk Reduction: ACC Experts

Michael O'Riordan

August 06, 2020

News Daily News

Semaglutide Cuts Risk of Major Cardiovascular Events in Type 2 Diabetes: SUSTAIN-6

Michael O'Riordan

September 16, 2016

News Industry News

First CVD Outcome Trial of a GLP-1 Agonist Finds No Cardiac Risk or Benefit

June 09, 2015

Advertisement

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

Better Outcomes and Lower Cost with Bariatric Surgery Over GLP-1s

Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT

SELECT: Semaglutide’s Impact on CVD Events Emerges Quickly

US Obesity Epidemic Continues to Skyrocket, With No End in Sight

Bariatric Surgery Reduces Hard Events in Obese Patients With Sleep Apnea

April 2024 Dispatch for the CV Team

One in Three Overweight MI Patients May Benefit From Semaglutide

TCTMD’s Top 10 Most Popular Stories for December 2023

Top Coronary Artery Disease News of 2023

Diabetes in Middle Age Linked to Earlier CVD Risk: Danish Study

Skyrocketing Popularity Puts GLP-1 Agonists for Weight Loss on Cardiology’s Radar

Fewer MACE in Diabetic Patients Taking SGLT2 Inhibitors vs DPP-4 Inhibitors

New Guidance on Use of Diabetes Drugs for CVD Risk Reduction: ACC Experts

Semaglutide Cuts Risk of Major Cardiovascular Events in Type 2 Diabetes: SUSTAIN-6

First CVD Outcome Trial of a GLP-1 Agonist Finds No Cardiac Risk or Benefit

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content